NBIX:NSD-Neurocrine Biosciences Inc (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 109.75

Change

+0.07 (+0.06)%

Market Cap

USD 9.54B

Volume

1.82M

Analyst Target

USD 140.29
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-05 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
UTHR United Therapeutics Corporatio..

+4.10 (+1.39%)

USD 13.14B
VTRS Viatris Inc

-0.06 (-0.69%)

USD 9.00B
LNTH Lantheus Holdings Inc

-0.76 (-0.70%)

USD 7.11B
ALKS Alkermes Plc

-0.38 (-1.20%)

USD 4.74B
HCM HUTCHMED DRC

+0.12 (+0.80%)

USD 2.63B
ALVO Alvotech

+0.11 (+1.34%)

USD 2.57B
SUPN Supernus Pharmaceuticals Inc

-0.45 (-1.37%)

USD 1.80B
ANIP ANI Pharmaceuticals Inc

-0.39 (-0.53%)

USD 1.51B
INDV Indivior PLC Ordinary Shares

-0.08 (-0.67%)

USD 1.44B
BCRX BioCryst Pharmaceuticals Inc

+2.10 (+23.52%)

USD 1.43B

ETFs Containing NBIX

IBRN iShares Trust - iShares N.. 4.36 % 0.00 %

-0.59 (-2.54%)

USD 2.92M
PSIL AdvisorShares Psychedelic.. 4.21 % 0.00 %

-0.14 (-2.54%)

USD 8.03M
CURE:AU ETFS S&P Biotech ETF 2.58 % 0.00 %

-0.30 (-2.54%)

USD 0.04B
JSMD Janus Henderson Small/Mid.. 2.54 % 0.50 %

-0.30 (-2.54%)

USD 0.44B
LABS 0.00 % 0.45 %

N/A

N/A
MDYG SPDR® S&P 400 Mid Cap Gr.. 0.00 % 0.15 %

-0.06 (-2.54%)

N/A
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

-0.35 (-2.54%)

N/A
SDG iShares MSCI Global Impac.. 0.00 % 0.49 %

+0.09 (+-2.54%)

USD 0.16B
DRDR:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

N/A

N/A
HEAL:LSE iShares Healthcare Innova.. 0.00 % 0.00 %

N/A

N/A
FBT:LSE First Trust Global Funds .. 0.00 % 0.00 %

N/A

USD 8.18M
FBTU:LSE First Trust Global Funds .. 0.00 % 0.00 %

N/A

USD 8.18M

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -19.60% 48% F 34% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -19.60% 48% F 34% F
Trailing 12 Months  
Capital Gain -22.55% 59% D- 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -22.55% 59% D- 37% F
Trailing 5 Years  
Capital Gain 6.06% 68% D+ 47% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.06% 68% D+ 41% F
Average Annual (5 Year Horizon)  
Capital Gain 6.63% 47% F 60% D-
Dividend Return 6.63% 46% F 57% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 21.57% 99% N/A 73% C
Risk Adjusted Return 30.74% 79% B- 65% D
Market Capitalization 9.54B 99% N/A 93% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.